BEDFORD, Mass., Oct. 1, 2007 /PRNewswire-FirstCall/ -- Hologic, Inc. (NASDAQ: HOLX), a leading provider of diagnostic imaging and state-of-the-art digital imaging systems directed towards women's health, today announced it will open the NASDAQ Stock Market tomorrow, October 2, 2007, in New York at 9:30AM ET in recognition of National Breast Cancer Awareness Month, commemorated annually on October 1st. The Company has been listed on NASDAQ for seventeen years. Chairman and CEO of Hologic, Jack Cumming, will preside over the NASDAQ opening bell ceremony at the NASDAQ Market Site, located at 4 Times Square, New York City.
"We are honored and proud to open the NASDAQ Stock Market and emphasize our commitment to advancing the fight against breast cancer and bringing hope to those affected by this deadly disease," said Cumming. "The breast cancer statistics are staggering. Breast cancer is the most frequently diagnosed cancer in women."
The American Cancer Society reports that over 240,000 new cases of breast cancer are diagnosed each year, one of eight women will get this deadly disease. More than 40,000 American women will die from breast cancer this year. "The good news," Cumming said "is that thanks to breast cancer screening programs and improvements in technology, death rates from breast cancer have steadily decreased in women since 1990."
One example of Hologic's commitment to women's health is the recently completed acquisition of BioLucent, the maker of MammoPad, a clinically proven radiolucent breast cushion. Hologic believes many women avoid or delay mammograms for fear of discomfort. The disposable MammoPad creates a cushion between the woman and the mammography system -- making the experience more comfortable and ultimately less stressful. In addition, Hologic believes with the use of the MammoPad, there is improved tissue acquisition, which may aid the technologist in improved patient positioning. Clinical studies show that three out of four women experience an average 50% decrease in discomfort with MammoPad. More than 12 million women have already benefited from MammoPad.
In honor of Breast Cancer Awareness, Hologic plans to include a starter case of MammoPads with all digital mammography systems shipped this month in the United States with the hope of introducing more clinicians, technologists and women to this most beneficial and very simple to use technology. Hologic intends to launch multiple programs over the next year to "spread the news" about MammoPad, with the hope of making it accessible to all women.
"The associates of Hologic share one goal," Cumming said. "That goal is to work together to advance technology for women's health. Early detection can significantly improve a woman's chance of surviving breast cancer and we remain passionately committed to improving women's healthcare by providing a comprehensive portfolio of tools and innovations to aid in early detection. It is our hope that increased awareness will encourage more women to include screening mammography as part of their routine medical care."
To view the opening of the NASDAQ Stock Market "live" on October 2, 2007, at 9:15AM ET, visit http://www.nasdaq.com/reference/marketsite_about.stm. Scroll down to the bottom of the page to access the Market Site live web cam link. Windows media player is required to view the web cam.
Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic and medical imaging systems dedicated to serving the healthcare needs of women, and a leading developer of innovative imaging technology for digital radiography and breast imaging. Hologic's core business units are focused on mammography and breast biopsy, osteoporosis assessment, and mini C-arm and extremity MRI imaging for orthopedic applications. For more information visit http://www.hologic.com/.
Forward Looking Statement Disclaimer
This News Release contains forward-looking information that involves risks and uncertainties, including statements regarding Hologic's plans, objectives, expectations and intentions. Such statements include, without limitation, statements regarding the anticipated benefits of Hologic's acquisition of BioLucent and related plans. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated. Risks and uncertainties that may cause these forward looking statements to vary materially from Hologic's expectations, include, among others: problems may arise with the ability of Hologic to successfully integrate the businesses of BioLucent, which may result in the combined company not operating as effectively and efficiently as expected; Hologic may not be able to achieve the expected synergies from the acquisition or it may take longer than expected to achieve those synergies; the acquisition may involve unexpected costs or unexpected liabilities, or the effects of purchase accounting may be different from Hologic's expectations; and the combined company may be adversely affected by future legislative, regulatory, or tax changes as well as other economic, business and/or competitive factors. Other factors that could adversely affect Hologic's business and prospects are described in Hologic's filings with the Securities and Exchange Commission. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Hologic's expectations or any change in events, conditions or circumstances on which any such statement is based.
Executive Vice President and CFO
Director, Investor Relations
Tel: (781) 999-7377
SOURCE: Hologic, Inc.